Immunotherapy combo shows promise against sarcoma in early trial

NCT ID NCT04968106

Ongoing Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding the immunotherapy drug retifanlimab to standard chemotherapy before surgery can improve outcomes for people with resectable soft-tissue sarcoma. About 66 participants will receive either chemotherapy alone or chemotherapy plus retifanlimab. The main goal is to see if the combination leads to a better tumor response in the surgical sample.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Retifanlimab (a drug that helps the immune system fight cancer) plus chemotherapy (doxorubicin and ifosfamide)
What this could lead to: If successful, this could lead to a new treatment option that improves tumor shrinkage before surgery and delays sarcoma recurrence.
What could go wrong: This is an early-phase trial with only 66 participants, so results may not apply to all sarcoma patients. Adding immunotherapy to chemotherapy can increase side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE SARCOMA

Contacts and locations

Locations

Centre Léon Bérard

Lyon, France
Institut Bergonié

Bordeaux, 33076, France
Institut Curie

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.